Cell therapy (CAR-T) · Kills target cells, directed at CD33 · developed by Vor Biopharma
VCAR33 is an allogeneic CAR T-cell therapy derived from matched healthy donor stem cell transplant recipients and engineered to express a chimeric antigen receptor targeting CD33. It is designed to recognize and kill CD33-expressing myeloid leukemia cells and is being studied in acute myeloid leukemia.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05984199 | Phase 1/2 | Leukemia, Myeloid, Acute | Terminated | VOR |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Leukemia, Myeloid, Acute
Updated Oct 3, 2026. Something wrong or missing? Report it on the VOR page.
See VOR's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
VOR catalysts and pipeline →